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EW PERSPECTIVES IN PULMONOLOGY
ong-term  oxygen  therapy  (LTOT)  revisited:  In defense
f traditional  LTOT  systems
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n  the  last  two  decennia  the  stationary  oxygen  concentra-
or  has  been  the  most  cost  effective  oxygen  source  for  most
atients  using  long-term  oxygen  therapy  (LTOT).1 In  most
ountries  the  oxygen  concentrator  has,  therefore,  largely
eplaced  stationary  oxygen  cylinders  with  a  volume  of
0  litres  or  more.2 The  oxygen  concentrator  is  very  conve-
ient  and  safe  for  home  use.  However,  for  patients  needing
n  oxygen  ﬂow  rate  of  >  3  L/min  the  oxygen  concentration
elivered  may  be  insufﬁcient  to  meet  the  patient’s  oxygena-
ion  needs.3
At  present,  stationary  oxygen  cylinders  are  only  being
sed  as  a  back  up  for  the  oxygen  concentrator  in  case  of
ower  failure  or  in  the  rare  circumstance  that  there  is  no
lectrical  power.  Small  oxygen  cylinders  for  ambulatory  use
re,  however,  still  being  used  to  a  great  extent.  They  are
ade  of  aluminium,  composite  or  steel.  Their  capacity  is
etermined  by  their  volume  and  pressurization,  which  may
o  up  to  200  bars  in  steel  cylinders.  Their  capacity  remains,
onetheless,  small  and  decreases  even  further  with  less
eight.  To  increase  their  capacity  they  may  be  supplied
ith  a  demand  oxygen  delivery  system  (DODS),  but  the  clin-
cal  performance  of  these  devices  is  highly  variable  and  may
ontribute  to  limitations  in  exercise  tolerance.4
For  patients  who  are  still  active  the  liquid  oxygen  system
ay  be  a  better  alternative.  This  system  is  not  only  reliable
nd  very  convenient  for  both  home  and  ambulatory  use  but
t  also  provides  high  oxygen  purity,  irrespective  of  the  oxy-
en  ﬂow  rate  used.5 With  a  continuous  ﬂow  rate  of  1  L/min
atients  may  stay  away  from  home  for  a  whole  day.  Even
atients  with  a  continuous  ﬂow  rate  of  3  L/min  may  stay
way  from  the  stationary  canister  for  as  long  as  10  h  if  they
se  two  portable  canisters.  If  combined  with  an  oxygen  con-
erving  device,  such  as  a  transtracheal  catheter  or  a  DODS,
his  may  even  double.  In  order  to  reduce  the  full  weight  of
 DOI of refers to article: http://dx.doi.org/10.1016/j.rppneu.
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ttp://dx.doi.org/10.1016/j.rppneu.2012.04.003he  portable  canister  (2.2--6.0  kg  for  a volume  of  1.0--2.0  L
f  liquid  oxygen)  smaller  canisters  with  an  integrated  DODS
ave  been  developed.  As  with  small  oxygen  cylinders  and  a
ODS  it  is,  however,  questionable  if  the  maximum  setting  on
he  portable  containers  is  able  to  meet  the  patient’s  oxy-
enation  needs.  A  major  disadvantage  of  all  liquid  oxygen
ystems  is  the  requirement  for  pressure  relief  venting.  The
ffect  is  that  oxygen  is  consumed  even  if  the  patient  does
ot  use  it.  Another  drawback  is  that  the  different  systems
re  incompatible  with  each  other.  For  out-of-town  travel,
his  factor  takes  on  a particular  signiﬁcance.  Finally,  the
igh  costs  of  the  liquid  oxygen  system  in  comparison  to  an
xygen  concentrator  may  explain  why  at  present  this  con-
enient  oxygen  source  is  provided  less  often  than  10  years
go.6
By  far  the  majority  of  patients  using  LTOT  suffer  from
OPD,  and  most  of  them  spend  most  of  their  time  in  and
round  their  house.  They  are  generally  at  rest  but  occasion-
lly  they  may  perform  some  light  activities.  These  patients
sually  can  be  oxygenated  effectively  most  of  the  day  by
n  oxygen  concentrator.  For  patients  who  cannot  be  oxy-
enated  sufﬁciently  with  an  oxygen  concentrator,  a  liquid
xygen  system  seems  justiﬁed.  Only  patients  who  are  still
ctive,  and  who  desire  and  are  able  to  leave  their  home
ould  need  a  portable  oxygen  source.  For  most  of  them  an
xygen  cylinder  with  a  capacity  of  3--6  h  at  a  continuous  ﬂow
ate  of  1.0--2.0  L/min  would  sufﬁce  to  visit  a  friend  or  to  do
ome  shopping,  at  least  in  Europe  where  travelling  time  is
sually  not  very  long.  The  patient  needing  an  oxygen  ﬂow
ate  >  2.0  L/min  and  who  wants  to  leave  her/his  house  sev-
ral  times  per  week  for  more  than  3  h  could  be  enabled  to
se  oxygen  nearly  all  the  time  by  means  of  a liquid  oxygen
ystem,  particularly  if  combined  with  an  oxygen  conserving
evice.With  the  development  of  non-delivery  LTOT  technology
atients  were  given  unlimited  access  to  portable  oxygen.7
irst,  special  concentrators  were  developed  that  are  able
o  safely  reﬁll  reusable  gaseous  cylinders  or  liquid  oxygen
gia.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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canisters  in  several  hours  at  home.  However,  as  patients
still  remained  dependent  on  their  home  stationary  unit,
two  types  of  portable  oxygen  concentrators  (POCs)  were
created.  One  type  can  deliver  oxygen  only  in  the  pulse-
dose-mode,  while  the  other  is  capable  of  delivering  oxygen
in  either  the  continuous-ﬂow  (0.5--3.0  L/min)  or  pulse-dose
mode.  The  latter  type  weighs,  however,  7.7  kg  and,  unlike
pulse-dose-mode  only  types  (2.7--4.5  kg),  cannot  be  carried
in  a  shoulder  bag.  This  new  technology  gives  LTOT  patients
more  freedom  than  ever,  since  they  are  no  longer  depen-
dent  on  oxygen  providers  for  frequent  deliveries  to  reﬁll  or
replace  depleted  oxygen  sources.
While  the  new  non-delivery  technology  may  certainly
have  its  beneﬁts,  there  are  several  drawbacks,  which  may
hamper  the  widespread  use  of  this  technology,  particu-
larly  in  Europe.  First,  due  to  the  low  weight  of  the  POCs
the  oxygen  production  capacity  is  limited  to  no  more  than
1.0  L/min.  Higher  ﬂow  rates  can  only  be  achieved  in  the
pulse-dose  mode.  However,  while  usually  preserving  ade-
quate  oxygenation  at  rest,  POCs  like  DODS  may  not  always
be  able  to  prevent  serious  desaturation  if  the  respiratory
rate  increases,  as  may  occur  during  increased  activity,  dur-
ing  an  exacerbation  or  in  an  aeroplane.4,8,9 This  may  be
caused  by  the  decrease  of  the  ratio  of  oxygen  from  the
POC  to  entrained  air,  thus  decreasing  the  relative  inspira-
tory  oxygen  fraction.  Second,  although  the  pulse-mode  may
be  acceptable  during  exercise,  several  patients  do  not  like
it  at  rest  or  during  sleep.  Besides  the  risk  of  non-compliance
this  also  raises  important  questions  about  the  effectiveness
of  providing  oxygen  continuously.  Third,  the  batteries  are
quite  heavy,  the  battery  life  (1--8  h)  may  still  prevent  a  wide
range  of  action,  especially  at  higher  ﬂow  settings,  and  in
case  of  malfunctioning  or  power  failure  there  is  no  back-up.
Fourth,  there  is  a  lack  of  standardization  and  the  settings
on  the  control  panel  of  each  POC  do  not  speciﬁcally  reﬂect
the  actual  bolus  size  in  mL.  It  is,  however,  the  volume  of  the
pulse  dose  and  not  the  pulse  dose  setting  that  determines
the  actual  delivered  oxygen  dose  to  the  patient  (in  L/min  or
mL  per  breath).  This  underlines  the  importance  of  a  titra-
tion  study,  and  not  only  whenever  a  patient  is  set  up  on  a
POC.  Subsequent  reassessments,  also  during  and  following
acute  exacerbations,  remain  necessary  to  ensure  that  the
selected  pulse-dose  settings  remain  effective.9,10 In  many
European  countries,  however,  oxygen  is  still  not  regarded
as  a  medicine  needing  a  proper  dose.  Oxygen  titration  is
neither  reimbursed  nor  performed  much,  and  usually  only
at  rest.  The  potential  for  serious  under-treatment  is  thus
real.  Indeed,  the  beneﬁts  reported  from  the  use  of  LTOT  are
observed  only  with  the  effective  and  prolonged  correction
of  hypoxemia.11 Finally,  unlike  the  US  with  its  long  distances
and  desire  for  mobility,  for  most  patients  in  Europe  this
technology  seems  unnecessary.  Likewise,  OCDs  have  never
become  popular  in  Europe.  Without  any  incentive  for  the159
rescribing  physician,  without  clear  overall  cost  effective-
ess  for  most  patients  and  with  the  low  and  ﬂat  price  oxygen
roviders  receive  nowadays,  many  if  not  most  LTOT  patients
n  Europe  will  probably  keep  their  traditional  LTOT  systems.
In  conclusion,  although  non-delivery  LTOT  technology
eems  to  offer  more  freedom  than  the  traditional  LTOT  sys-
ems  there  is  a  serious  risk  of  insufﬁcient  oxygenation,  which
ay  reduce  or  even  annul  the  goal  of  LTOT  itself:  to  improve
urvival  and  the  quality  of  life  by  assuring  adequate  oxy-
enation  at  all  times.  Only  if  there  were  proof  that  this
echnology  is  able  to  meet  this  goal  of  LTOT,  in  the  home
etting  under  conditions  of  real  life,  could  it  be  prescribed
or  selected  patients.  Until  then,  further  research  is  needed
o  demonstrate  that  the  same  endpoints  can  be  attained
sing  pulse-dose-only  delivery  devices,  like  OCDs,  as  with
he  traditional  LTOT  systems.
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